hotspot -WSS

hotspot

author：comprehensive 2025-09-30 18:20:43 - browse：9

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： ALS groups 'won't be played again' by the FDA, drug sponsors

focus

WSS

Abbott's new heart device gets FDA advisory panel nod

Covid isolation guidance eased by the CDC

AstraZeneca loses challenge to Medicare drug price negotiation

Medical device lobby: We're tired of waiting on Medicare coverage

Flu vaccine offering decent levels of protection this winter, new data show

Medical device lobby: We're tired of waiting on Medicare coverage

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

Medicare details structure of new drug price negotiation program

International team creates first chimeric human

BioMarin wins approval for gene therapy to treat hemophilia A

Congress gives doctors Medicare pay bump

Medicare details structure of new drug price negotiation program

Flu vaccine offering decent levels of protection this winter, new data show

Dobbs anniversary: the lost opportunity of abortion as health care

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Affirmative action in medical school literally saved lives

ACIP vaccine advisory panel sees its vacancies filled

explore

Tome Biosciences co

ALS groups 'won't be played again' by the FDA, drug sponsors

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Juul documents reveal insider tactics on political lobbying

FogPharma raises $145 million in rare Series E round

Tome Biosciences co

focus

leisure time

leisure time

leisure time